Telomerase-independent paths to immortality in predictable cancer subtypes.
about
Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNACellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active siteThe Role of ATRX in the Alternative Lengthening of Telomeres (ALT) PhenotypeGenetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma CellsTumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences.Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring.PML body meets telomere: the beginning of an ALTernate ending?DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.Nuclear condensation and cell cycle arrest induced by telomerase siRNA in neuroblastoma cells.Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis.Break-induced replication and genome stability.Telomere shortening is associated with reduced duodenal HCOFormula secretory but normal gastric acid secretory capacity in aging mice.The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.Alternative lengthening of telomeres does exist in various canine sarcomas.Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
P2860
Q27690211-536C4550-CEB5-413B-921A-569821FBF40CQ27727694-6A143BAB-EF7D-4447-A2E0-762CE0982ECFQ28071562-2D69FCAF-97C9-4453-BE41-D11586F0C525Q28118722-B291B180-699A-46E1-A503-68D87B2020DAQ33687535-0EB067E4-DF01-42E3-9C4A-1FACF56ACCE9Q33815938-B3109948-490D-4E67-9BE0-3AF4645005E3Q36409202-923A52B8-CAA0-4FC8-9D5B-26097264BB2FQ37534945-AE0FA865-BE87-4E57-90FC-12DB0209739CQ38008909-22A4751A-2301-4A38-B3E5-771F419474EBQ38376116-148CE95F-1C17-43F2-A23A-43C44196E141Q39226403-A61BAB70-FF94-4815-AA80-6C0A4EE2460BQ40066773-AEC5293C-EAA4-4669-8932-DA6CD36EA9CCQ42039020-938CE887-D846-40DC-8C0B-E3535B72F3E2Q42513414-33935617-4E0C-464D-9B99-3FAFFBF7B553Q43955301-4DB1BEEA-D16E-4B29-BF0E-4BCBC967839CQ44866615-F65A437A-3859-4557-84D7-F0EEB195B42AQ48014113-6465C753-DE08-4946-B6DF-43EFE0480A89Q48915503-7055FA65-071C-40B5-8119-89024B85425E
P2860
Telomerase-independent paths to immortality in predictable cancer subtypes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Telomerase-independent paths to immortality in predictable cancer subtypes.
@en
Telomerase-independent paths to immortality in predictable cancer subtypes.
@nl
type
label
Telomerase-independent paths to immortality in predictable cancer subtypes.
@en
Telomerase-independent paths to immortality in predictable cancer subtypes.
@nl
prefLabel
Telomerase-independent paths to immortality in predictable cancer subtypes.
@en
Telomerase-independent paths to immortality in predictable cancer subtypes.
@nl
P2860
P356
P1433
P1476
Telomerase-independent paths to immortality in predictable cancer subtypes.
@en
P2093
Stephen T Durant
P2860
P356
10.7150/JCA.3965
P577
2012-01-31T00:00:00Z